Neurol. praxi. 2013;14(6):309-313

Acute stroke and antihypertensive treatment

MUDr.Jan Fiksa1, MUDr.Tomáš Janota, CSc.2
1 Neurologická klinika 1. LF UK a VFN, Praha
2 III. interní klinika 1. LF UK a VFN, Praha

The acute hypertensive response occurs in more than 50% of all patients with acute stroke. However the treatment of hypertension in

acute stroke is controversial, very high as well as low blood pressure have deleterious effect. In a consensus statement the American

Heart Association and American Stroke Association has arbitrarily set for patients with hemorrhage stroke a systolic blood pressure of

more than 200mmHg as target levels for aggressive management and more modest reduction when systolic blood pressure is more than

180mmHg. The blood pressure targets for patients with ischemic stroke eligible for thrombolytic therapy have been set at a systolic blood

pressure less than 185mmHg and diastolic blood pressure less than 110mmHg and after use of reperfusion therapy systolic blood pressure

less than 180mmHg and diastolic blood pressure less than 105 mmHg. For patients with ischemic stroke without reperfusion therapy the

AHA/ASA has set systolic blood pressure over 220 mmHg or diastolic blood pressure over 120 mmHg as a target of therapy. Within the

first hour blood pressure decline cannot exceed 20%, as a optimal decline is considered 10%. Fast but short acting intravenous (IV) antihypertensive

drugs are preferred for the accurate titration of the effect. IV antihypertensive drugs with side effect of steal phenomenon,

worsening of brain oedema or intracranial hypertension are to be excluded.

Keywords: acute stroke, antihypertensive treatment, blood pressure targets

Published: December 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fiksa J, Janota T. Acute stroke and antihypertensive treatment. Neurol. praxi. 2013;14(6):309-313.
Download citation

References

  1. Aiyagari V, Gorelick PB. Management of blood pressure for acute and recurrent stroke. Stroke 2009; 40(6): 2251-2256. Go to original source... Go to PubMed...
  2. Anderson CS, Huang Y, Want JG, Amina H, Neal B, Leny B, Heeley E, Skulina CH, Pardone MW, Kim JS, Tao QL, Li YCH, Juany JD, Tai LW, Zhang JL, Xu E, Cheng Y, Heritier S, Morgenstern LB, Chalmers J. Intensive blood pressure reduction in acute cerebral hemorrhage trial (INTERACT): a randomized pilot trial. Lancet Neurol 2008; 7: 391-399. Go to original source... Go to PubMed...
  3. Anderson CS, Heeley E, Huang Y, Wang JG, Wang J, Stapf CH, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, Heritier S, Li O, Woodward M, Simek J, Davis SM, Chalmers J, for the INTERACT2 Investigators. Rapid blood pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013; 368: 2355-2365. Go to original source... Go to PubMed...
  4. Arima H, Huang Y, Wang JG, Heeley E, Delcourt C, Parsons M, Li Q, Neal B, Chalmers J, Anderson C, for the INTERACT1 Investigators. Earlier blood pressure-lowering and greater attenuation of hematoma growth in acute intracerebral hemorrhage. Stroke 2012; 43: 2236-2238. Go to original source... Go to PubMed...
  5. Becker KJ, Baxter AB, Bybee HM, Tirschwell DL, Abouelsaad T, Cohen WA. Extravasation of radiographic contrast is an independent predictor of death in primary intracerebral hemorrhage. Stroke 1999; 30: 2025-2032. Go to original source... Go to PubMed...
  6. Britton M, Carlsson A. Very high blood pressure in acute stroke. J Intern Med 1990;228: 611-615. Go to original source... Go to PubMed...
  7. Brott T, Lu M, Kothari R, Fagan SC, Frankel M, Grotta JC, Broderick J, Kwiatkowski T, Lewandowski CH, Haley C, Marler JR, Tilley BC. Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke 1998; 29: 1504-1509. Go to original source... Go to PubMed...
  8. COSSACS Trial Group. COSSACS (Continue or Stop post-Stroke Antihypertensives Collaborative Study): rationale and design. J Hypertens 2005; 23(2): 455-458. Go to original source... Go to PubMed...
  9. England TJ, Bath PM, Sare GM, Geeganage CH, Moulin T, O´Neill D, Woimant F, Christensen H, Deyn P, Leys D, Ringelstein B. Asymptomatic Hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the Tinzaparinin Acute Ischaemic Stroke Trial. Stroke 2010; 41: 2834-2839. Go to original source... Go to PubMed...
  10. Feldstein C. Management of hypertensive crises. Am J Ther 2007; 14: 135-139. Go to original source... Go to PubMed...
  11. Leonardi-Bee J, Bath PMW, Phillips SJ, Sandercock AG. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002; 33: 1315-1320. Go to original source... Go to PubMed...
  12. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358: 2127-2137. Go to original source... Go to PubMed...
  13. Morfis I, Schwartz RS, Poulos R, Howes LG. Blood pressure changes in acute cerebral infarction and haemorrhage. Stroke 1997;28: 1401-1405. Go to original source... Go to PubMed...
  14. Ntaios G, Lambrou D, Michel P. Blood pressure changes in acute ischemic stroke and outcome with respect to stroke etiology. Neurology 2012; 79: 1440-1448. Go to original source... Go to PubMed...
  15. Ohkuma H, Tsurutani H, Suzuki S. Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. Stroke 2001; 32: 1176-1180. Go to original source... Go to PubMed...
  16. Tikhonoff V, Zhang H, Richart T, Staessen JA. Blood pressure as a prognostic factor after acute stroke, Lancet Neurol 2009; 8(10): 938-948. Go to original source... Go to PubMed...
  17. Wada R, Aviv RI, Fox AJ, Sahlas DJ, Gladstone DJ, Tomlinson G, Symons SP. CT angiography, ,spot" sign predicts hematoma expansion in acute intracerebral hemorrhage. Stroke 2007; 38: 1257-1262. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.